Domain Adoption: Senior Virologist and Epidemiologist.

Abstract:

This episode of This Week in Virology (TWIV) focuses on herpesviruses, presenting two primary scientific studies. The first is an ancient DNA analysis tracing the diversity and germline integration of human beta herpesvirus 6A and 6B (HHV-6A/B) over 2,500 years, confirming their prevalence and lineage association with contemporary clades, particularly within European populations. The second discussion centers on a large-scale epidemiological study from Wales examining the effect of Herpes Zoster (shingles) vaccination (Zostavax, live attenuated) on cognitive decline and mortality. Utilizing a strict date-of-birth eligibility threshold as a natural randomization method, the study demonstrated that vaccination significantly reduced new diagnoses of mild cognitive impairment and decreased all-cause and dementia-specific mortality in individuals living with dementia. Notably, this protective effect was found to be statistically significant primarily among women.

TWIV 1287: Herpesvirus Genomics and Vaccination Policy

• 0:00 Introduction and Setup: The episode, recorded January 9th, 2026, features hosts Vincent Racaniello, Rich Condit, Alan Dove, and Brienne Barker. Initial discussion focuses on microbial sciences programming and soliciting support for MicrobeTV.
• 0:49 New Research Opportunity: Announcement of a post-doctoral and technician recruitment for the Amy Rosenfeld Lab (Mainline Health and Lankanau Institute for Medical Research) focusing on viral pathogenesis and immunobiology related to cross-reactive anti-enterovirus immune responses.
• 6:06 ASV Meeting Dates: Reminder regarding the American Society for Virology (ASV) 2026 meeting (July 27-30) in Minneapolis. Abstract deadline is February 2nd, and travel award deadline is February 9th.
• 7:13 Denmark's Vaccine Schedule Context: Alan Dove discusses a Science article explaining Denmark's pared-down vaccination schedule (e.g., no universal Hep B vaccine). This policy is attributed to Denmark’s robust, universal healthcare system and extremely low rates of certain endemic diseases (like Hepatitis B), making the cost-benefit ratio for universal vaccination unfavorable—a distinction lost on US policymakers citing Denmark as inspiration.
• 11:24 First Paper: Ancient HHV-6 DNA: Presentation of a Science Advances paper, "Tracing 2500 years of human beta herpesvirus 6A and 6B diversity through ancient DNA."
  • 13:17 HHV-6 Background: HHV-6B is highly prevalent (90% infection rate in children by age two), often causing roseola infantum ("sixth disease"). HHV-6A is less prevalent, with infections occurring mostly in adulthood.
  • 19:22 Unique Latency Mechanism: Unlike other human herpesviruses (which maintain latency extrachromosomally), HHV-6 can integrate into human telomeres, particularly in the germline, allowing for vertical transmission (0.4–1% of the population).
  • 24:30 Ancient Findings: Researchers screened ~4,000 ancient DNA samples, identifying 11 individuals (8th century BCE to 14th century CE, primarily European) with integrated HHV-6A (6 samples) and HHV-6B (5 samples).
  • 27:10 Integration Confirmation: Detection of the virus in both tooth and bone samples (e.g., individual EDI1) confirms inherited germline integration in ancient populations.
  • 33:09 Key Takeaway on Clades: All known inherited integrated HHV-6A clades were present in historical European populations, suggesting HHV-6A may no longer be newly integrating into the germline, unlike HHV-6B.
• 38:54 Second Paper: Shingles Vaccine and Dementia: Discussion of a Cell paper, "The effect of shingles vaccination at different stages of the dementia disease course."
  • 41:40 Study Methodology: The study leverages the live attenuated Zostavax vaccine rollout by the UK National Health Service, which used a strict date-of-birth eligibility cutoff (September 2, 1933) to create highly comparable cohorts, minimizing confounding variables.
  • 44:54 Cognitive Impairment Reduction: Among individuals without prior cognitive impairment, eligibility for Zostavax decreased the occurrence of new mild cognitive impairment diagnoses by 1.5 percentage points (equating to a 3.1 percentage point reduction for those actually vaccinated) over a nine-year follow-up.
  • 48:39 Mortality Reduction: Among patients with pre-existing dementia, actual receipt of the vaccine resulted in a 29% reduction in deaths due to dementia over nine years.
  • 52:26 Gender Bias: The statistically significant protective effect on cognitive impairment and mortality was found almost entirely in women, suggesting immunological or epidemiological sex differences.
  • 55:07 Dementia Stage Efficacy: The protective effect on mortality was greater for individuals with more advanced dementia.
  • 56:19 All-Cause Mortality: Vaccination was associated with a 22.7% reduction in all-cause mortality over nine years (mainly in women). Non-dementia associated deaths were not affected.
  • 1:02:17 Long-Term Implications: Discussion addresses the long-term population-level effects on dementia as universal Varicella (chickenpox) vaccination replaces natural infection.
• 1:05:17 Listener Mail & Picks: Topics include browser caching issues affecting MicrobeTV website visibility, anti-vaccine rhetoric, the importance of longitudinal data (as used in the Zostavax study), and a pedagogical resource aligning This Week in Microbiology (TWIM) episodes with key learning objectives.